Panakeia (“the Company”), a pioneer in AI-driven multi-omic biomarker profiling, today announces the launch of PANProfiler Colon, an AI-driven software solution for profiling of Microsatellite instability (MSI) and mismatch repair deficiency (dMMR) entirely digitally and directly from Hematoxylin and Eosin (H&E)-stained images of colon cancer tissue samples.
Leveraging AI and proprietary insights into colorectal cancer biology, PANProfiler Colon is the second clinical product originating from Panakeia’s PANProfiler multi-omic biomarker profiling platform. PANProfiler Colon is registered for use in the UK (UKCA-marked), while the PANProfiler platform is available for Research Use Only (RUO) and can profile biomarkers in over 30 cancer types for patient screening and clinical trials.
PANProfiler Colon is designed to determine MSI/dMMR status from H&E-stained images of colon cancer tissue samples from patients within minutes, accelerating the diagnosis process and empowering pathologists and oncologists to make treatment decisions leading to personalized treatment and improved outcomes for patients.
MSI and dMMR are hallmarks of colorectal cancer (CRC) and can identify cases of Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC). Testing for these markers has become routine clinical practice and is also key to informing downstream treatment decisions by oncologists.
Professor David Harrison MD, DSc, FRCPath, FRCPEd, FRCSEd, Professor of Pathology at the University of St Andrews, Director of iCAIRD and Consultant in NHS Lothian, commented: “PANProfiler Colon is the second profiling tool generated by Panakeia and its PANProfiler platform, the utility of which was explored by the Industrial Centre for Artificial Intelligence Research in Digital Diagnostics consortium.
“Receiving an early cancer diagnosis can vastly improve a patient’s experience and treatment outcomes. We continue to be impressed by the quality of the results generated by PANProfiler’s entirely digital molecular profiling. We look forward to continuing working with the team to uncover further time and resource saving solutions to benefit patients.”
The launch of PANProfiler Colon is another key milestone for Panakeia. We are committed to making precision medicine accessible across the globe and continue to deliver on this vision by releasing our second product for use in colon cancer MSI/dMMR molecular profiling.
Our PANProfiler suite of solutions has the potential to revolutionize precision medicine providing an end-to-end solution for biomarker profiling across the drug discovery, development and clinical decision making pathways.”
Pahini Pandya, Founder and Chief Executive Officer, Panakeia
The release of PANProfiler Colon follows that of PANProfiler Breast, with both products currently deployed in multiple hospitals across the UK.
Results of a blinded multi-site validation study of PANProfiler Colon will be presented at this year’s American Society of Clinical Oncology Gastrointestinal Cancers Symposium.
New drug cocktail enhances CAR-T cells for cancer treatment